首页 > 最新文献

World journal of clinical oncology最新文献

英文 中文
Hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma: A case report. 转移性肝细胞癌的低分次和调强放疗联合全身治疗:病例报告。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1342
Qiu-Qiu Chen, Chun-Qiao Chen, Jin-Kun Liu, Ming-Yue Huang, Min Pan, Hui Huang

Background: Liver cancer treatment is characterized by multidisciplinary participation and coexistence of multiple treatment methods. Hypofractionated and intensity-modulated radiotherapy is a new precise radiotherapy technique applied to the treatment of systemic malignant tumors. There is a lack of understanding of hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma (HCC).

Case summary: We report a case of metastatic HCC treated with hypofractionated and intensity-modulated radiotherapy combined with systemic therapy. A 41-year-old man was diagnosed with metastatic HCC (T3N1M1 stage IVB). Because it was found to be in the late stage of cancer and had already metastasized, it was impossible to undergo surgical treatment. In addition to aggressive comprehensive treatment for the primary lesion, local treatment for metastatic cancer can improve the patient's survival potential. Hypofractionated and intensity-modulated radiotherapy can provide a larger single treatment dose within a shorter overall treatment time, and improve the local control rate of the tumor. Follow-up examination demonstrated that the tumor and metastatic lesions had shrunk after therapy. The treatment has showed good efficacy. The patient survived for 18 months without disease progression and stable disease persisted for > 38 months.

Conclusion: Targeted therapy and immunotherapy followed by hypofractionated and intensity-modulated radiotherapy are also effective for advanced metastatic HCC.

背景:肝癌治疗的特点是多学科参与和多种治疗方法并存。低分次调强放疗是一种新的精确放疗技术,适用于全身恶性肿瘤的治疗。病例摘要:我们报告了一例转移性肝细胞癌(HCC)采用低分割调强放疗联合全身治疗的病例。一名 41 岁的男性被诊断为转移性 HCC(T3N1M1 IVB 期)。由于发现时已是癌症晚期并已发生转移,因此无法进行手术治疗。除了对原发病灶进行积极的综合治疗外,转移癌的局部治疗也能提高患者的生存率。低分次放疗和调强放疗可以在较短的总体治疗时间内提供较大的单次治疗剂量,提高肿瘤的局部控制率。随访检查显示,治疗后肿瘤和转移病灶均已缩小。治疗效果良好。患者存活了 18 个月,病情未见恶化,疾病稳定期超过 38 个月:结论:靶向治疗和免疫治疗,再配合低分次和调强放疗,对晚期转移性 HCC 同样有效。
{"title":"Hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma: A case report.","authors":"Qiu-Qiu Chen, Chun-Qiao Chen, Jin-Kun Liu, Ming-Yue Huang, Min Pan, Hui Huang","doi":"10.5306/wjco.v15.i10.1342","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1342","url":null,"abstract":"<p><strong>Background: </strong>Liver cancer treatment is characterized by multidisciplinary participation and coexistence of multiple treatment methods. Hypofractionated and intensity-modulated radiotherapy is a new precise radiotherapy technique applied to the treatment of systemic malignant tumors. There is a lack of understanding of hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma (HCC).</p><p><strong>Case summary: </strong>We report a case of metastatic HCC treated with hypofractionated and intensity-modulated radiotherapy combined with systemic therapy. A 41-year-old man was diagnosed with metastatic HCC (T3N1M1 stage IVB). Because it was found to be in the late stage of cancer and had already metastasized, it was impossible to undergo surgical treatment. In addition to aggressive comprehensive treatment for the primary lesion, local treatment for metastatic cancer can improve the patient's survival potential. Hypofractionated and intensity-modulated radiotherapy can provide a larger single treatment dose within a shorter overall treatment time, and improve the local control rate of the tumor. Follow-up examination demonstrated that the tumor and metastatic lesions had shrunk after therapy. The treatment has showed good efficacy. The patient survived for 18 months without disease progression and stable disease persisted for > 38 months.</p><p><strong>Conclusion: </strong>Targeted therapy and immunotherapy followed by hypofractionated and intensity-modulated radiotherapy are also effective for advanced metastatic HCC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1342-1350"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision at scale: Machine learning revolutionizing laparoscopic surgery. 大规模的精确性:机器学习彻底改变腹腔镜手术。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1256
Carlos M Ardila, Daniel González-Arroyave

In their recent study published in the World Journal of Clinical Cases, the article found that minimally invasive laparoscopic surgery under general anesthesia demonstrates superior efficacy and safety compared to traditional open surgery for early ovarian cancer patients. This editorial discusses the integration of machine learning in laparoscopic surgery, emphasizing its transformative potential in improving patient outcomes and surgical precision. Machine learning algorithms analyze extensive datasets to optimize procedural techniques, enhance decision-making, and personalize treatment plans. Advanced imaging modalities like augmented reality and real-time tissue classification, alongside robotic surgical systems and virtual reality simulations driven by machine learning, enhance imaging and training techniques, offering surgeons clearer visualization and precise tissue manipulation. Despite promising advancements, challenges such as data privacy, algorithm bias, and regulatory hurdles need addressing for the responsible deployment of machine learning technologies. Interdisciplinary collaborations and ongoing technological innovations promise further enhancement in laparoscopic surgery, fostering a future where personalized medicine and precision surgery redefine patient care.

他们最近在《世界临床病例杂志》(World Journal of Clinical Cases)上发表的研究文章发现,与传统的开腹手术相比,全身麻醉下的微创腹腔镜手术对早期卵巢癌患者的疗效和安全性更胜一筹。这篇社论讨论了机器学习与腹腔镜手术的整合,强调了机器学习在改善患者预后和手术精准度方面的变革潜力。机器学习算法通过分析大量数据集来优化手术技术、加强决策制定和个性化治疗方案。增强现实和实时组织分类等先进的成像模式,以及由机器学习驱动的机器人手术系统和虚拟现实模拟,增强了成像和训练技术,为外科医生提供了更清晰的可视化和精确的组织操作。尽管取得了可喜的进步,但要负责任地部署机器学习技术,还需要应对数据隐私、算法偏差和监管障碍等挑战。跨学科合作和持续的技术创新有望进一步提高腹腔镜手术的水平,促进个性化医疗和精准手术重新定义患者护理的未来。
{"title":"Precision at scale: Machine learning revolutionizing laparoscopic surgery.","authors":"Carlos M Ardila, Daniel González-Arroyave","doi":"10.5306/wjco.v15.i10.1256","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1256","url":null,"abstract":"<p><p>In their recent study published in the <i>World Journal of Clinical Cases</i>, the article found that minimally invasive laparoscopic surgery under general anesthesia demonstrates superior efficacy and safety compared to traditional open surgery for early ovarian cancer patients. This editorial discusses the integration of machine learning in laparoscopic surgery, emphasizing its transformative potential in improving patient outcomes and surgical precision. Machine learning algorithms analyze extensive datasets to optimize procedural techniques, enhance decision-making, and personalize treatment plans. Advanced imaging modalities like augmented reality and real-time tissue classification, alongside robotic surgical systems and virtual reality simulations driven by machine learning, enhance imaging and training techniques, offering surgeons clearer visualization and precise tissue manipulation. Despite promising advancements, challenges such as data privacy, algorithm bias, and regulatory hurdles need addressing for the responsible deployment of machine learning technologies. Interdisciplinary collaborations and ongoing technological innovations promise further enhancement in laparoscopic surgery, fostering a future where personalized medicine and precision surgery redefine patient care.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1256-1263"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative management of postoperative sigmoid colon cancer complicated by a large abdominal wall defect: A case report. 乙状结肠癌术后并发巨大腹壁缺损的围手术期处理:病例报告。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1333
Yan-Ling Zhu, Rui Li, Yuan-Guang Cheng, Ya-Fei Wang

Background: Large abdominal wall defect (LAWD) measures > 20 cm in width. LAWD can easily lead to intestinal necrosis, peritonitis, other complications, and even multiple organ dysfunction syndrome. Multiple intestinal fistulas are high-flow fistulas that can cause severe water-electrolyte imbalance and malnutrition, as well as inflammation, high metabolic status, and chronic intestinal failure caused by intestinal fluid corrosion in tissues around the orifice fistulas.

Case summary: This article summarizes the nursing experience of a patient with sigmoid carcinoma who has LAWD with multiple intestinal fistula due to repeated operations for postoperative complications. The key points of care: Scientific assessment of nutritional status, dynamic adjustment of nutritional support programmes, comprehensive adoption of enteral nutrition, parenteral nutrition and combined nutrition of enteral and parenteral; taking good care of abdominal wall defects and intestinal fistulas; continuous flushing of the abdominal drainage tube and low negative pressure drainage; prevention of venous thrombosis; strengthening of physical exercise; implementation of positive psychological interventions.

Conclusion: After more than 7 months of careful care, the patient's physical fitness has been well recovered, local inflammation is well controlled, which wins the opportunity for the operation, and the postoperative recovery is good.

背景:大腹壁缺损(LAWD)的宽度大于 20 厘米。腹壁缺损容易导致肠坏死、腹膜炎、其他并发症,甚至多器官功能障碍综合征。多发性肠瘘属于高流量肠瘘,可引起严重的水电解质失衡和营养不良,同时由于肠液腐蚀肠瘘口周围组织,导致炎症、高代谢状态和慢性肠功能衰竭。病例摘要:本文总结了一名乙状结肠癌患者因术后并发症反复手术导致LAWD合并多发性肠瘘的护理经验。护理要点科学评估营养状况,动态调整营养支持方案,综合采用肠内营养、肠外营养及肠内、肠外联合营养;做好腹壁缺损、肠瘘的护理;持续冲洗腹腔引流管,低负压引流;预防静脉血栓形成;加强体育锻炼;实施积极的心理干预:经过7个多月的精心护理,患者体质恢复良好,局部炎症控制良好,为手术赢得了机会,术后恢复良好。
{"title":"Perioperative management of postoperative sigmoid colon cancer complicated by a large abdominal wall defect: A case report.","authors":"Yan-Ling Zhu, Rui Li, Yuan-Guang Cheng, Ya-Fei Wang","doi":"10.5306/wjco.v15.i10.1333","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1333","url":null,"abstract":"<p><strong>Background: </strong>Large abdominal wall defect (LAWD) measures > 20 cm in width. LAWD can easily lead to intestinal necrosis, peritonitis, other complications, and even multiple organ dysfunction syndrome. Multiple intestinal fistulas are high-flow fistulas that can cause severe water-electrolyte imbalance and malnutrition, as well as inflammation, high metabolic status, and chronic intestinal failure caused by intestinal fluid corrosion in tissues around the orifice fistulas.</p><p><strong>Case summary: </strong>This article summarizes the nursing experience of a patient with sigmoid carcinoma who has LAWD with multiple intestinal fistula due to repeated operations for postoperative complications. The key points of care: Scientific assessment of nutritional status, dynamic adjustment of nutritional support programmes, comprehensive adoption of enteral nutrition, parenteral nutrition and combined nutrition of enteral and parenteral; taking good care of abdominal wall defects and intestinal fistulas; continuous flushing of the abdominal drainage tube and low negative pressure drainage; prevention of venous thrombosis; strengthening of physical exercise; implementation of positive psychological interventions.</p><p><strong>Conclusion: </strong>After more than 7 months of careful care, the patient's physical fitness has been well recovered, local inflammation is well controlled, which wins the opportunity for the operation, and the postoperative recovery is good.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1333-1341"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute severe hypokalemia caused by treatment of tongue squamous cell carcinoma with docetaxel and cisplatin: A case report. 多西他赛和顺铂治疗舌鳞状细胞癌引起的急性严重低钾血症:病例报告。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1309
Hong-Mei Jiang, Rong Sun, Bing-Jie Ning, Xue-Qin Yang, Xiao-Ju Zhu

Background: The tongue squamous cell carcinoma (TSCC) is an oral malignant tumor arising from the squamous epithelium of the tongue mucosa, characterized by a high malignant degree, invasive growth, early lymph node metastasis, and poor prognosis. Paclitaxel, represented by docetaxel, is now the standard first-line treatment for head and neck squamous cell carcinoma. Docetaxel, which belongs to the class of drugs known as paclitaxel, is an antitumor drug that inhibits cell mitosis and proliferation. Its adverse effects include myelosuppression, hair loss, gastrointestinal reactions, fluid retention, and allergic reactions. However, hypokalemia is rare, most cases are mild or moderate, and severe hypokalemia is seldom reported.

Case summary: During chemotherapy with docetaxel and cisplatin, a patient with TSCC developed severe hypokalemia. His potassium level was found to have been reduced to 1.85 mmol/L at the most critical situation. The patient had grade 1 muscle strength in all four limbs and could not perform any action, which was considered to be a sign of severe hypokalemia. Measures taken included intravenous infusion via micro-pump, intravenous injection, and oral potassium supplement, which gradually improved muscle strength and serum potassium levels. The patient survived the critical period of severe hypokalemia after chemotherapy. He was generally in good condition following treatment and discharged in stable condition.

Conclusion: Docetaxel may cause severe hypokalemia with hypomagnesemia and the mechanism for this is not yet known to researchers yet. This means that nurses specializing in chemotherapy must exercise a high degree of responsibility, closely observe the patient's reaction to the anticancer medication, notice any symptoms of adverse effects early. It is necessary to be considerate regarding individual differences between patients when selecting chemotherapy regimens and adhere to the principle of individualized treatment. Following multiple cycles of chemotherapy, patients should be aware of the accumulation of toxic side effects and receive blood tests reviewed within 24 hours of completion. It is essential to monitor electrolyte levels in patients suffering from severe gastrointestinal reactions to avoid complications that may result in death.

背景:舌鳞状细胞癌(TSCC)是一种发生于舌粘膜鳞状上皮的口腔恶性肿瘤,具有恶性程度高、浸润性生长、淋巴结转移早、预后差等特点。目前,以多西他赛为代表的紫杉醇是头颈部鳞癌的标准一线治疗药物。多西他赛属于紫杉醇类药物,是一种抑制细胞有丝分裂和增殖的抗肿瘤药物。其不良反应包括骨髓抑制、脱发、胃肠道反应、体液潴留和过敏反应。病例摘要:一名 TSCC 患者在接受多西他赛和顺铂化疗期间出现了严重的低钾血症。在最危急的情况下,他的血钾水平降至 1.85 mmol/L。患者四肢肌力均为 1 级,无法完成任何动作,这被认为是严重低钾血症的征兆。所采取的措施包括通过微型泵静脉输液、静脉注射和口服补钾药物,从而逐渐改善了患者的肌力和血清钾水平。患者度过了化疗后严重低钾血症的关键时期。他在治疗后总体状况良好,病情稳定后出院:结论:多西他赛可能会导致严重的低钾血症和低镁血症,目前研究人员还不清楚其机制。这意味着化疗专科护士必须具有高度的责任心,密切观察患者对抗癌药物的反应,及早发现不良反应症状。在选择化疗方案时要考虑患者的个体差异,坚持个体化治疗原则。多周期化疗后,患者应注意毒副反应的积累,并在化疗结束后 24 小时内接受血液检查复查。对于出现严重胃肠道反应的患者,必须监测其电解质水平,以避免出现可能导致死亡的并发症。
{"title":"Acute severe hypokalemia caused by treatment of tongue squamous cell carcinoma with docetaxel and cisplatin: A case report.","authors":"Hong-Mei Jiang, Rong Sun, Bing-Jie Ning, Xue-Qin Yang, Xiao-Ju Zhu","doi":"10.5306/wjco.v15.i10.1309","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1309","url":null,"abstract":"<p><strong>Background: </strong>The tongue squamous cell carcinoma (TSCC) is an oral malignant tumor arising from the squamous epithelium of the tongue mucosa, characterized by a high malignant degree, invasive growth, early lymph node metastasis, and poor prognosis. Paclitaxel, represented by docetaxel, is now the standard first-line treatment for head and neck squamous cell carcinoma. Docetaxel, which belongs to the class of drugs known as paclitaxel, is an antitumor drug that inhibits cell mitosis and proliferation. Its adverse effects include myelosuppression, hair loss, gastrointestinal reactions, fluid retention, and allergic reactions. However, hypokalemia is rare, most cases are mild or moderate, and severe hypokalemia is seldom reported.</p><p><strong>Case summary: </strong>During chemotherapy with docetaxel and cisplatin, a patient with TSCC developed severe hypokalemia. His potassium level was found to have been reduced to 1.85 mmol/L at the most critical situation. The patient had grade 1 muscle strength in all four limbs and could not perform any action, which was considered to be a sign of severe hypokalemia. Measures taken included intravenous infusion <i>via</i> micro-pump, intravenous injection, and oral potassium supplement, which gradually improved muscle strength and serum potassium levels. The patient survived the critical period of severe hypokalemia after chemotherapy. He was generally in good condition following treatment and discharged in stable condition.</p><p><strong>Conclusion: </strong>Docetaxel may cause severe hypokalemia with hypomagnesemia and the mechanism for this is not yet known to researchers yet. This means that nurses specializing in chemotherapy must exercise a high degree of responsibility, closely observe the patient's reaction to the anticancer medication, notice any symptoms of adverse effects early. It is necessary to be considerate regarding individual differences between patients when selecting chemotherapy regimens and adhere to the principle of individualized treatment. Following multiple cycles of chemotherapy, patients should be aware of the accumulation of toxic side effects and receive blood tests reviewed within 24 hours of completion. It is essential to monitor electrolyte levels in patients suffering from severe gastrointestinal reactions to avoid complications that may result in death.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1309-1314"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Banxia xiexin decoction prevents the development of gastric cancer. 半夏泻心汤能预防胃癌的发生。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1293
Guo-Xiu Zu, Ke-Yun Sun, Xi-Jian Liu, Ji-Qin Tang, Hai-Liang Huang, Tao Han

Background: In China banxia xiexin decoction (BXD) has been used in treating gastric cancer (GC) for thousands of years and BXD has a good role in reversing GC histopathology, but its chemical composition and action mechanism are still unknown.

Aim: To investigate the mechanism of action of BXD against GC based on transcriptomics, network pharmacology, in vivo and in vitro experiments.

Methods: The transplanted tumor model was prepared, and the nude mouse were pathologically examined after administration, and hematoxylin-eosin staining was performed. The active ingredients of BXD were quality controlled and identified using ultra-performance liquid chromatography tandem quadrupole electrostatic field orbitrap mass spectrometry (UPLC-Q-Orbitrap MS/MS), and traditional Chinese medicines systems pharmacology platform, drug bank and the Swiss target prediction platform to predict the relevant targets, the differentially expressed genes (DEGs) of GC were screened by RNA-seq sequencing, and the overlapping targets were analyzed to obtain the key targets and pathways. Cell Counting Kit-8, apoptosis assay, cell migration and Realtime fluorescence quantitative polymerase chain reaction were used for in vitro experiments.

Results: All dosing groups inhibited the growth of transplanted tumors in laboratory-bred strain nude, with the capecitabine group and the BXD medium-dose group being the best. A total of 29 compounds and 859 potential targets in BXD were identified by UPLC-Q-Orbitrap MS/MS and network pharmacology, RNA-seq sequencing found 4767 GC DEGs, which were combined with network pharmacology and analyzed 246 potential therapeutic targets were obtained and pathway results showed that BXD may against GC through the Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKt) signaling pathway. In vitro cellular experiments confirmed that BXD-containing serum and LY294002 could inhibit the proliferation of GC cells, promote apoptosis, and inhibit the migration of GC cells by decreasing the expression of EGFR, PIK3CA, IL6, BCL2 and AKT1 in the PI3K-Akt pathway in MGC-803 expression.

Conclusion: BXD has the effect of inhibiting tumor growth rate and delaying the development of GC. Its mechanism of action may be related to the regulation of PI3K-Akt signaling pathway.

背景:目的:基于转录组学、网络药理学、体内和体外实验,研究半夏泻心汤(BXD)对胃癌的作用机制:方法:制备移植瘤模型,给药后对裸鼠进行病理检查,并进行苏木精-伊红染色。采用超高效液相色谱-串联四极杆静电场轨道质谱(UPLC-Q-Orbitrap MS/MS)对BXD的有效成分进行质量控制和鉴定,利用中药系统药理学平台、药物库和瑞士靶点预测平台预测相关靶点,利用RNA-seq测序筛选GC的差异表达基因(DEGs),分析重叠靶点,获得关键靶点和通路。体外实验采用了细胞计数试剂盒-8、细胞凋亡检测、细胞迁移和实时荧光定量聚合酶链反应:结果:所有剂量组均能抑制实验室培育的裸鼠移植肿瘤的生长,其中卡培他滨组和 BXD 中剂量组效果最好。通过UPLC-Q-Orbitrap MS/MS和网络药理学共鉴定出BXD中的29个化合物和859个潜在靶点,RNA-seq测序发现4767个GC DEGs,结合网络药理学分析得到246个潜在治疗靶点,通路结果显示BXD可通过磷酸肌酸3-激酶(PI3K)/蛋白激酶B(AKt)信号通路对抗GC。体外细胞实验证实,含BXD的血清和LY294002可通过降低MGC-803表达的PI3K-Akt通路中表皮生长因子受体(EGFR)、PIK3CA、IL6、BCL2和AKT1的表达,抑制GC细胞的增殖,促进细胞凋亡,抑制GC细胞的迁移:结论:BXD具有抑制肿瘤生长和延缓GC发展的作用。结论:BXD具有抑制肿瘤生长、延缓GC发展的作用,其作用机制可能与PI3K-Akt信号通路的调节有关。
{"title":"Banxia xiexin decoction prevents the development of gastric cancer.","authors":"Guo-Xiu Zu, Ke-Yun Sun, Xi-Jian Liu, Ji-Qin Tang, Hai-Liang Huang, Tao Han","doi":"10.5306/wjco.v15.i10.1293","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1293","url":null,"abstract":"<p><strong>Background: </strong>In China banxia xiexin decoction (BXD) has been used in treating gastric cancer (GC) for thousands of years and BXD has a good role in reversing GC histopathology, but its chemical composition and action mechanism are still unknown.</p><p><strong>Aim: </strong>To investigate the mechanism of action of BXD against GC based on transcriptomics, network pharmacology, <i>in vivo</i> and <i>in vitro</i> experiments.</p><p><strong>Methods: </strong>The transplanted tumor model was prepared, and the nude mouse were pathologically examined after administration, and hematoxylin-eosin staining was performed. The active ingredients of BXD were quality controlled and identified using ultra-performance liquid chromatography tandem quadrupole electrostatic field orbitrap mass spectrometry (UPLC-Q-Orbitrap MS/MS), and traditional Chinese medicines systems pharmacology platform, drug bank and the Swiss target prediction platform to predict the relevant targets, the differentially expressed genes (DEGs) of GC were screened by RNA-seq sequencing, and the overlapping targets were analyzed to obtain the key targets and pathways. Cell Counting Kit-8, apoptosis assay, cell migration and Realtime fluorescence quantitative polymerase chain reaction were used for <i>in vitro</i> experiments.</p><p><strong>Results: </strong>All dosing groups inhibited the growth of transplanted tumors in laboratory-bred strain nude, with the capecitabine group and the BXD medium-dose group being the best. A total of 29 compounds and 859 potential targets in BXD were identified by UPLC-Q-Orbitrap MS/MS and network pharmacology, RNA-seq sequencing found 4767 GC DEGs, which were combined with network pharmacology and analyzed 246 potential therapeutic targets were obtained and pathway results showed that BXD may against GC through the Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKt) signaling pathway. <i>In vitro</i> cellular experiments confirmed that BXD-containing serum and LY294002 could inhibit the proliferation of GC cells, promote apoptosis, and inhibit the migration of GC cells by decreasing the expression of <i>EGFR</i>, <i>PIK3CA</i>, <i>IL6</i>, <i>BCL2</i> and <i>AKT1</i> in the PI3K-Akt pathway in MGC-803 expression.</p><p><strong>Conclusion: </strong>BXD has the effect of inhibiting tumor growth rate and delaying the development of GC. Its mechanism of action may be related to the regulation of PI3K-Akt signaling pathway.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1293-1308"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cervical myeloid sarcoma as an initial clinical manifestation: Four case reports. 作为初始临床表现的宫颈髓样肉瘤:四份病例报告
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1324
Jin-Ke Li, Xiao-Xue Wang, Jia-Jun Fu, Dan-Dan Zhang

Background: Cervical myeloid sarcoma (MS) is a rare hematological malignancy characterized by the formation of extramedullary soft tissue masses in the cervical region. Due to its uncommon presentation in the female reproductive system, cervical MS poses significant diagnostic and therapeutic challenges. Consequently, there is a pressing need for more research and clinical experience to better understand, diagnose, and manage this condition effectively.

Case summary: This report details four cases, the diagnostic process, treatment strategy, and outcomes, discussing cervical MS as an initial clinical manifestation. The disease exhibits varied clinical presentations, such as irregular vaginal bleeding and palpation of cervical masses. The treatment approaches discussed include neoadjuvant chemotherapy, surgery, and postoperative chemotherapy, though managing the disease remains challenging. The report also features a comprehensive literature review that underscores the importance of immunohistochemistry for accurate diagnosis, identifying key markers, including myeloperoxidase, cluster of differentiation (CD) 68, and CD43, stressing the need for further research to improve treatment strategies and prognosis.

Conclusion: Immunohistochemical diagnosis and tailored therapeutic strategies are essential. Further research is crucial in improving outcomes and developing effective treatment protocols.

背景:宫颈髓样肉瘤(MS)是一种罕见的血液恶性肿瘤,其特点是在宫颈区域形成髓外软组织肿块。由于宫颈髓样肉瘤在女性生殖系统中并不常见,因此给诊断和治疗带来了巨大挑战。因此,迫切需要更多的研究和临床经验,以更好地理解、诊断和有效管理这种疾病。病例摘要:本报告详细介绍了四例病例、诊断过程、治疗策略和结果,讨论了宫颈 MS 这一最初的临床表现。该病的临床表现多种多样,如不规则阴道出血和宫颈肿块触诊。讨论的治疗方法包括新辅助化疗、手术和术后化疗,但该疾病的治疗仍具有挑战性。报告还进行了全面的文献综述,强调了免疫组化对准确诊断的重要性,确定了包括髓过氧化物酶、分化簇(CD)68 和 CD43 在内的关键标记物,强调了进一步研究以改善治疗策略和预后的必要性:结论:免疫组化诊断和有针对性的治疗策略至关重要。结论:免疫组化诊断和有针对性的治疗策略至关重要,进一步的研究对于改善预后和制定有效的治疗方案至关重要。
{"title":"Cervical myeloid sarcoma as an initial clinical manifestation: Four case reports.","authors":"Jin-Ke Li, Xiao-Xue Wang, Jia-Jun Fu, Dan-Dan Zhang","doi":"10.5306/wjco.v15.i10.1324","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1324","url":null,"abstract":"<p><strong>Background: </strong>Cervical myeloid sarcoma (MS) is a rare hematological malignancy characterized by the formation of extramedullary soft tissue masses in the cervical region. Due to its uncommon presentation in the female reproductive system, cervical MS poses significant diagnostic and therapeutic challenges. Consequently, there is a pressing need for more research and clinical experience to better understand, diagnose, and manage this condition effectively.</p><p><strong>Case summary: </strong>This report details four cases, the diagnostic process, treatment strategy, and outcomes, discussing cervical MS as an initial clinical manifestation. The disease exhibits varied clinical presentations, such as irregular vaginal bleeding and palpation of cervical masses. The treatment approaches discussed include neoadjuvant chemotherapy, surgery, and postoperative chemotherapy, though managing the disease remains challenging. The report also features a comprehensive literature review that underscores the importance of immunohistochemistry for accurate diagnosis, identifying key markers, including myeloperoxidase, cluster of differentiation (CD) 68, and CD43, stressing the need for further research to improve treatment strategies and prognosis.</p><p><strong>Conclusion: </strong>Immunohistochemical diagnosis and tailored therapeutic strategies are essential. Further research is crucial in improving outcomes and developing effective treatment protocols.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1324-1332"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma. 全面评估肿瘤浸润免疫细胞与肾细胞癌预后之间的关联。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.5306/wjco.v15.i10.1280
Guo-Hao Wei, Xi-Yi Wei, Ling-Yao Fan, Wen-Zheng Zhou, Ming Sun, Chuan-Dong Zhu

Background: According to current statistics, renal cancer accounts for 3% of all cancers worldwide. Renal cell carcinoma (RCC) is the most common solid lesion in the kidney and accounts for approximately 90% of all renal malignancies. Increasing evidence has shown an association between immune infiltration in RCC and clinical outcomes. To discover possible targets for the immune system, we investigated the link between tumor-infiltrating immune cells (TIICs) and the prognosis of RCC.

Aim: To investigate the effects of 22 TIICs on the prognosis of RCC patients and identify potential therapeutic targets for RCC immunotherapy.

Methods: The CIBERSORT algorithm partitioned the 22 TIICs from the Cancer Genome Atlas cohort into proportions. Cox regression analysis was employed to evaluate the impact of 22 TIICs on the probability of developing RCC. A predictive model for immunological risk was developed by analyzing the statistical relationship between the subpopulations of TIICs and survival outcomes. Furthermore, multivariate Cox regression analysis was used to investigate independent factors for the prognostic prediction of RCC. A value of P < 0.05 was regarded as statistically significant.

Results: Compared to normal tissues, RCC tissues exhibited a distinct infiltration of immune cells. An immune risk score model was established and univariate Cox regression analysis revealed a significant association between four immune cell types and the survival risk connected to RCC. High-risk individuals were correlated to poorer outcomes according to the Kaplan-Meier survival curve (P = 1E-05). The immunological risk score model was demonstrated to be a dependable predictor of survival risk (area under the curve = 0.747) via the receiver operating characteristic curve. According to multivariate Cox regression analysis, the immune risk score model independently predicted RCC patients' prognosis (hazard ratio = 1.550, 95%CI: 1.342-1.791; P < 0.001). Finally, we established a nomogram that accurately and comprehensively forecast the survival of patients with RCC.

Conclusion: TIICs play various roles in RCC prognosis. The immunological risk score is an independent predictor of poor survival in kidney cancer cases.

背景:根据目前的统计数据,肾癌占全球癌症总数的 3%。肾细胞癌(RCC)是肾脏中最常见的实体瘤,约占所有肾脏恶性肿瘤的 90%。越来越多的证据表明,RCC 中的免疫浸润与临床结果之间存在关联。为了发现免疫系统的可能靶点,我们研究了肿瘤浸润免疫细胞(TIIC)与RCC预后之间的联系。目的:研究22种TIIC对RCC患者预后的影响,并确定RCC免疫疗法的潜在治疗靶点:方法:CIBERSORT算法将癌症基因组图谱队列中的22个TIIC按比例划分。方法:CIBERSORT算法将癌症基因组图谱队列中的22个TIIC划分为不同的比例,采用Cox回归分析评估22个TIIC对RCC发病概率的影响。通过分析 TIICs 亚群与生存结果之间的统计关系,建立了免疫风险预测模型。此外,还采用了多变量考克斯回归分析来研究预测RCC预后的独立因素。P<0.05为差异有统计学意义:结果:与正常组织相比,RCC组织表现出明显的免疫细胞浸润。免疫风险评分模型已经建立,单变量 Cox 回归分析显示,四种免疫细胞类型与 RCC 的生存风险有显著关联。根据 Kaplan-Meier 生存曲线(P = 1E-05),高风险人群的预后较差。通过接收者操作特征曲线,免疫学风险评分模型被证明是生存风险的可靠预测指标(曲线下面积 = 0.747)。根据多变量 Cox 回归分析,免疫风险评分模型可独立预测 RCC 患者的预后(危险比 = 1.550,95%CI:1.342-1.791;P <0.001)。最后,我们建立了一个能准确、全面预测RCC患者生存期的提名图:结论:TIIC在RCC预后中发挥着不同的作用。结论:TIIC在RCC预后中起着不同的作用,免疫学风险评分是肾癌患者不良生存率的独立预测因子。
{"title":"Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma.","authors":"Guo-Hao Wei, Xi-Yi Wei, Ling-Yao Fan, Wen-Zheng Zhou, Ming Sun, Chuan-Dong Zhu","doi":"10.5306/wjco.v15.i10.1280","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1280","url":null,"abstract":"<p><strong>Background: </strong>According to current statistics, renal cancer accounts for 3% of all cancers worldwide. Renal cell carcinoma (RCC) is the most common solid lesion in the kidney and accounts for approximately 90% of all renal malignancies. Increasing evidence has shown an association between immune infiltration in RCC and clinical outcomes. To discover possible targets for the immune system, we investigated the link between tumor-infiltrating immune cells (TIICs) and the prognosis of RCC.</p><p><strong>Aim: </strong>To investigate the effects of 22 TIICs on the prognosis of RCC patients and identify potential therapeutic targets for RCC immunotherapy.</p><p><strong>Methods: </strong>The CIBERSORT algorithm partitioned the 22 TIICs from the Cancer Genome Atlas cohort into proportions. Cox regression analysis was employed to evaluate the impact of 22 TIICs on the probability of developing RCC. A predictive model for immunological risk was developed by analyzing the statistical relationship between the subpopulations of TIICs and survival outcomes. Furthermore, multivariate Cox regression analysis was used to investigate independent factors for the prognostic prediction of RCC. A value of <i>P</i> < 0.05 was regarded as statistically significant.</p><p><strong>Results: </strong>Compared to normal tissues, RCC tissues exhibited a distinct infiltration of immune cells. An immune risk score model was established and univariate Cox regression analysis revealed a significant association between four immune cell types and the survival risk connected to RCC. High-risk individuals were correlated to poorer outcomes according to the Kaplan-Meier survival curve (<i>P</i> = 1<sup>E-05</sup>). The immunological risk score model was demonstrated to be a dependable predictor of survival risk (area under the curve = 0.747) <i>via</i> the receiver operating characteristic curve. According to multivariate Cox regression analysis, the immune risk score model independently predicted RCC patients' prognosis (hazard ratio = 1.550, 95%CI: 1.342-1.791; <i>P</i> < 0.001). Finally, we established a nomogram that accurately and comprehensively forecast the survival of patients with RCC.</p><p><strong>Conclusion: </strong>TIICs play various roles in RCC prognosis. The immunological risk score is an independent predictor of poor survival in kidney cancer cases.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1280-1292"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing postsurgical recovery for elderly patients with gastric cancer. 优化老年胃癌患者的术后恢复。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-09-24 DOI: 10.5306/wjco.v15.i9.1122
Adamu D Isah, Zakari Shaibu, Sheng-Chun Dang

Based on a recent study by Li et al, this editorial examines the significance of enhanced recovery after surgery (ERAS) protocols for elderly patients with gastric cancer. Cancer-related mortality, which is overwhelmingly caused by gastric cancer, calls for effective treatment strategies. Despite advances in the field of oncology, conventional postoperative care often results in prolonged hospital stays and increased complications. The aim of ERAS is to expedite recovery, reduce surgical stress, and improve patient satisfaction. The study of Li et al showed that, compared to traditional care, ERAS significantly reduces mortality risk, shortens hospital stays, and decreases postoperative complications. These findings support the widespread implementation of ERAS protocols in surgical practice to enhance patient outcomes and healthcare value.

这篇社论以 Li 等人最近的一项研究为基础,探讨了加强术后恢复(ERAS)方案对老年胃癌患者的意义。胃癌是导致癌症死亡的主要原因,因此需要采取有效的治疗策略。尽管肿瘤学领域取得了进步,但传统的术后护理往往导致住院时间延长和并发症增加。ERAS 的目的是加快康复,减轻手术压力,提高患者满意度。Li 等人的研究表明,与传统护理相比,ERAS 可显著降低死亡风险、缩短住院时间并减少术后并发症。这些研究结果支持在外科实践中广泛实施 ERAS 方案,以提高患者的治疗效果和医疗价值。
{"title":"Optimizing postsurgical recovery for elderly patients with gastric cancer.","authors":"Adamu D Isah, Zakari Shaibu, Sheng-Chun Dang","doi":"10.5306/wjco.v15.i9.1122","DOIUrl":"10.5306/wjco.v15.i9.1122","url":null,"abstract":"<p><p>Based on a recent study by Li <i>et al</i>, this editorial examines the significance of enhanced recovery after surgery (ERAS) protocols for elderly patients with gastric cancer. Cancer-related mortality, which is overwhelmingly caused by gastric cancer, calls for effective treatment strategies. Despite advances in the field of oncology, conventional postoperative care often results in prolonged hospital stays and increased complications. The aim of ERAS is to expedite recovery, reduce surgical stress, and improve patient satisfaction. The study of Li <i>et al</i> showed that, compared to traditional care, ERAS significantly reduces mortality risk, shortens hospital stays, and decreases postoperative complications. These findings support the widespread implementation of ERAS protocols in surgical practice to enhance patient outcomes and healthcare value.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 9","pages":"1122-1125"},"PeriodicalIF":2.6,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large-cell neuroendocrine carcinoma of the bladder: A case report. 膀胱大细胞神经内分泌癌:病例报告。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-09-24 DOI: 10.5306/wjco.v15.i9.1239
Yu Zhou, Lin Yang

Background: Bladder neuroendocrine tumors are few and exhibit a high degree of aggressiveness. The bladder is characterized by four distinct forms of neuroendocrine tumors. Among them, large-cell neuroendocrine carcinoma is the least prevalent, but has the highest level of aggressiveness. The 5-year survival rate for large-cell neuroendocrine carcinoma of the bladder is exceedingly poor. To date, only a few dozen cases have been reported.

Case summary: Here, we report the case of a 65-year-old man with large-cell neuroendocrine carcinoma of the bladder. The patient presented to the Department of Urology at our hospital due to the presence of painless hematuria without any identifiable etiology. During hospitalization, abdominal computed tomography revealed the presence of an irregular mass on the right anterior wall of the bladder. A cystoscopic non-radical resection of the bladder lesion was performed. The postoperative pathological examination revealed large-cell neuroendocrine bladder cancer. Previous reports on cases of large-cell neuroendocrine carcinoma cases were retrieved from PubMed, and the present paper discusses the currently recognized best diagnostic and treatment options for large-cell neuroendocrine carcinoma based on the latest research progress.

Conclusion: Large-cell neuroendocrine carcinoma of the bladder is an uncommon malignancy with a highly unfavorable prognosis. Despite ongoing efforts to prolong patient survival through multidisciplinary therapy, the prognosis remains unfavorable. Large-cell neuroendocrine carcinoma continues to be a subject of uncertainty.

背景:膀胱神经内分泌肿瘤为数不多,且具有高度侵袭性。膀胱有四种不同形式的神经内分泌肿瘤。其中,大细胞神经内分泌癌发病率最低,但侵袭性最强。膀胱大细胞神经内分泌癌的 5 年生存率极低。病例摘要:本文报告了一例 65 岁男性膀胱大细胞神经内分泌癌患者的病例。患者因出现无痛性血尿而到我院泌尿外科就诊,但无法确定病因。住院期间,腹部计算机断层扫描发现膀胱右前壁有一个不规则肿块。医生在膀胱镜下对膀胱病灶进行了非根治性切除。术后病理检查显示为大细胞神经内分泌膀胱癌。本文根据最新研究进展,讨论了目前公认的大细胞神经内分泌癌的最佳诊断和治疗方案:结论:膀胱大细胞神经内分泌癌是一种不常见的预后极差的恶性肿瘤。尽管目前正在努力通过多学科治疗延长患者的生存期,但预后仍然不容乐观。大细胞神经内分泌癌仍然是一个不确定的话题。
{"title":"Large-cell neuroendocrine carcinoma of the bladder: A case report.","authors":"Yu Zhou, Lin Yang","doi":"10.5306/wjco.v15.i9.1239","DOIUrl":"10.5306/wjco.v15.i9.1239","url":null,"abstract":"<p><strong>Background: </strong>Bladder neuroendocrine tumors are few and exhibit a high degree of aggressiveness. The bladder is characterized by four distinct forms of neuroendocrine tumors. Among them, large-cell neuroendocrine carcinoma is the least prevalent, but has the highest level of aggressiveness. The 5-year survival rate for large-cell neuroendocrine carcinoma of the bladder is exceedingly poor. To date, only a few dozen cases have been reported.</p><p><strong>Case summary: </strong>Here, we report the case of a 65-year-old man with large-cell neuroendocrine carcinoma of the bladder. The patient presented to the Department of Urology at our hospital due to the presence of painless hematuria without any identifiable etiology. During hospitalization, abdominal computed tomography revealed the presence of an irregular mass on the right anterior wall of the bladder. A cystoscopic non-radical resection of the bladder lesion was performed. The postoperative pathological examination revealed large-cell neuroendocrine bladder cancer. Previous reports on cases of large-cell neuroendocrine carcinoma cases were retrieved from PubMed, and the present paper discusses the currently recognized best diagnostic and treatment options for large-cell neuroendocrine carcinoma based on the latest research progress.</p><p><strong>Conclusion: </strong>Large-cell neuroendocrine carcinoma of the bladder is an uncommon malignancy with a highly unfavorable prognosis. Despite ongoing efforts to prolong patient survival through multidisciplinary therapy, the prognosis remains unfavorable. Large-cell neuroendocrine carcinoma continues to be a subject of uncertainty.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 9","pages":"1239-1244"},"PeriodicalIF":2.6,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blastic plasmacytoid dendritic cell neoplasm: Two case reports. 大疱性浆细胞树突状细胞瘤:两份病例报告。
IF 2.6 Q3 ONCOLOGY Pub Date : 2024-09-24 DOI: 10.5306/wjco.v15.i9.1207
Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu

Background: Blastic plasmacytoid dendritic cell tumor (BPDCN) is a rare and highly invasive lymphohematopoietic tumor that originates from plasmacytoid dendritic cells. BPDCN has an extremely poor prognosis. Skin lesions are usually the first manifestation of BPDCN, although the tumor may also invade the bone marrow, lymph nodes, peripheral blood, and other parts of the body, leading to several other manifestations, requiring further differentiation through skin biopsy and immunohistochemistry.

Case summary: In the present paper, the cases of 2 patients diagnosed with BPDCN are discussed. The immunohistochemistry analysis of these 2 patients revealed positivity for CD4, CD56, and CD123. Currently, no standard chemotherapy regimen is available for BPDCN. Therefore, intensive therapy for acute lymphoblastic leukemia was applied as the treatment method for these 2 cases.

Conclusion: Although allogeneic bone marrow transplantation could be further effective in prolonging the median survival the ultimate prognosis was unfavorable. Future treatment modalities tailored for elderly patients will help prolong survival.

背景:浆细胞性树突状细胞肿瘤(BPDCN)是一种罕见的高侵袭性淋巴造血肿瘤,起源于浆细胞性树突状细胞。BPDCN 的预后极差。皮肤病变通常是 BPDCN 的首发表现,但肿瘤也可能侵犯骨髓、淋巴结、外周血和身体其他部位,导致其他几种表现,需要通过皮肤活检和免疫组化进一步鉴别。这两名患者的免疫组化分析显示 CD4、CD56 和 CD123 阳性。目前,还没有针对 BPDCN 的标准化疗方案。因此,这 2 例患者采用了急性淋巴细胞白血病强化治疗方法:结论:虽然同种异体骨髓移植能进一步有效延长中位生存期,但最终预后并不乐观。未来针对老年患者的治疗方法将有助于延长生存期。
{"title":"Blastic plasmacytoid dendritic cell neoplasm: Two case reports.","authors":"Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu","doi":"10.5306/wjco.v15.i9.1207","DOIUrl":"10.5306/wjco.v15.i9.1207","url":null,"abstract":"<p><strong>Background: </strong>Blastic plasmacytoid dendritic cell tumor (BPDCN) is a rare and highly invasive lymphohematopoietic tumor that originates from plasmacytoid dendritic cells. BPDCN has an extremely poor prognosis. Skin lesions are usually the first manifestation of BPDCN, although the tumor may also invade the bone marrow, lymph nodes, peripheral blood, and other parts of the body, leading to several other manifestations, requiring further differentiation through skin biopsy and immunohistochemistry.</p><p><strong>Case summary: </strong>In the present paper, the cases of 2 patients diagnosed with BPDCN are discussed. The immunohistochemistry analysis of these 2 patients revealed positivity for CD4, CD56, and CD123. Currently, no standard chemotherapy regimen is available for BPDCN. Therefore, intensive therapy for acute lymphoblastic leukemia was applied as the treatment method for these 2 cases.</p><p><strong>Conclusion: </strong>Although allogeneic bone marrow transplantation could be further effective in prolonging the median survival the ultimate prognosis was unfavorable. Future treatment modalities tailored for elderly patients will help prolong survival.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 9","pages":"1207-1214"},"PeriodicalIF":2.6,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World journal of clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1